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Abstract
Functional and QoL outcomes were compared longitudinally in a cohort of patients 
treated for oropharyngeal squamous cell carcinoma (OPSCC) with primary transoral 
robotic surgery (TORS) or radiotherapy (RT). Forty-four patients undergoing pri-
mary TORS (n = 31) or RT (n = 13) for any stage OPSCC were included. Only low-
stage disease was treated with TORS. Functional outcomes were: salivary flow rate, 
image-based swallowing function, and a self-reported 10-point scale comparing cur-
rent swallowing function to baseline (CvB scale). QoL was assessed with European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
Core (EORTC QLQ-C30), Head & Neck Module (EORTC QLQ-HN35), and MD 
Anderson Dysphagia Inventory (MDADI). Shoulder impairment was assessed with 
Neck Dissection Impairment Index (NDII) and Oxford Shoulder Score (OSS). In 
the RT group, salivary flow rates had significantly declined at 12-month follow-up, 
with the biggest declines in QoL subscale scores recorded in the RT group for dry 
mouth and sticky saliva. Swallowing function on imaging studies was overall good, 
with no severe dysphagia within 1 year although, both treatment groups showed sig-
nificant deterioration relative to baseline at the 12-month follow-up with increased 
DIGEST scores and pharyngeal retention. Shoulder impairment was rare at 1 year 
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in both groups. A comprehensive examination of this cohort 
treated for OPSCC showed overall good functional and QoL 
outcomes 1 year after treatment. However, persistent impair-
ment was seen in both groups with regards to swallowing 
function. In the TORS group, at 12-months follow-up, the 
QoL questionnaires showed worse scores in only one sub-
scale (sticky saliva).
K E Y W O R D S
dysphagia, functional outcomes, oropharyngeal cancer, quality of life, 
radiotherapy, saliva, shoulder function, transoral robotic surgery
1 |  INTRODUCTION
The incidence of oropharyngeal cancers, including oropha-
ryngeal squamous cell carcinomas (OPSCC), is increasing 
mainly due to a sharp increase in HPV positive cancers in 
many countries.1,2 With a majority of OPSCC being HPV 
positive and, as HPV-positive OPSCC has a better progno-
sis, more patients become long-term cancer survivors, living 
with chronic adverse treatment side-effects.
With similar survival rates between primary surgical and 
primary oncological treatments,2-4 there is a need for com-
prehensive high-quality trials investigating the complications 
and adverse effects of available treatment options, particu-
larly with regards to long-term functional outcomes.
Considering this, we report a single-institutional obser-
vational prospective cohort study investigating functional 
and quality of life (QoL) outcomes in the first 12  months 
after treatment with either primary transoral robotic surgery 
(TORS group) or primary radiotherapy (RT group). This 
study was designed as a descriptive hypothesis-generating 
feasibility study, and therefore, cannot be used to compare 
treatment modalities. We present data for each group to in-
vestigate differences in modality specific adverse effects.
2 |  METHODS
Patients diagnosed with OPSCC, regardless of stage, were 
prospectively enrolled from May 2017 to October 2018 at 
the Department of Otorhinolaryngology, Audiology and 
Head & Neck Surgery at Copenhagen University Hospital 
(Rigshospitalet), Denmark.
Patients with verified OPSCC, WHO performance stage 
0–2, in the absence of distant metastasis, previous head and 
neck cancer or radiotherapy to the head and neck were eligi-
ble to participate.
TORS is considered an experimental treatment for OPSCC 
in Denmark and all patients in this cohort were offered pri-
mary oncological treatment. Patients with low-stage disease 
(T1-T2, N0-N1, M0 according to the union for international 
cancer control, IUCC 7th, edition) who were assessed as op-
erable without trismus or radiological signs of extra capsular 
extension in metastatic lymph nodes were also offered TORS 
and ipsi- or bilateral selective neck dissection. All except one 
patient, who were offered TORS, chose this treatment, which 
means that included patients treated with primary RT, were 
patients who did not qualify for TORS.
The study was conducted in accordance with the 
Declaration of Helsinki and was approved by the local eth-
ical committee (H-1-2014-033 and H-17015164). Written 
informed consent was obtained. The study protocol has been 
published on clinicalTrials.gov (NCT03418909).
2.1 | Treatment
2.1.1 | Surgery
The da Vinci SI Surgical System (Intuitive Surgical Inc) was 
used for all TORS procedures. Resection margins of >2 mm 
or supplementary free margins were considered negative 
margins.5,6 TORS was performed with concurrent neck dis-
section––if not already performed as part of our “cancer of 
unknown primary” diagnostic algorithm. For tonsillar malig-
nancies, a unilateral selective neck dissection was performed. 
A bilateral neck dissection was performed for midline ma-
lignancies; base of tongue and soft palate. Selective neck 
dissection was performed according to local guidelines. 
Adjuvant RT was recommended in case of positive margins, 
extra nodal extension (ENE), or more than one involved 
lymph node.
2.1.2 | Radiotherapy
In this study, patients with biopsy confirmed T-stage >2 
and/or N-stage >1 with M-stage =0 (according to UICC7) 
were offered RT (with or without chemotherapy). RT was 
delivered using volumetric arc therapy (VMAT). Target 
volumes consisted of a gross tumor volume (GTV) with 
tumor tissue verified by imaging data and clinical exami-
nation, including macroscopically involved lymph nodes. 
This was encompassed by a clinical target volume, CTV1, 
with a 5–10 mm margin from GTV. If a 5 mm expansion 
was used for CTV1, a CTV2 encompassed CTV1 with a 
concentric margin of 5 mm was added. CTV3 encompassed 
CTV2 and also included low risk regional elective lymph 
node regions. Accelerated radiotherapy with 6 fractions/
week was standard. CTV1 received 68 Gy/34 fractions if 
the macroscopic tumor exceeded 4  cm in largest diame-
ter, otherwise 66  Gy/33 fractions. A minimum of 60  Gy 
was prescribed to CTV2, and 50 Gy to CTV3. Fit patients 
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with T3-T4 or N+ disease were offered concurrent chemo-
therapy with Cisplatin 40  mg/m2 weekly. Nimorazole, a 
radiosensitizer, was offered all patients receiving primary 
radiotherapy.
Adjuvant RT comprised 66 Gy to areas of residual tumor, 
involved resection margin or ENE, 60 Gy to the remaining 
tumor-bed and 50 Gy to the elective volumes as described 
in primary radiotherapy. Fit patients with positive margins 
(<2  mm) or ENE were offered concurrent chemotherapy 
with Cisplatin 40 mg/m2 weekly.
2.2 | Data collection
Pretreatment data included age, sex, smoking history, 
American Society of Anesthesiologists (ASA) score, and 
weight. After treatment start, the following data were col-
lected: uni- or bilateral neck treatment, aspiration pneumo-
nias, tracheotomies, hemorrhages, re-resections, adjuvant 
treatment, admissions/re-admissions including indication for 
admission, recurrences, progression, and death.
Study parameters, including QoL outcomes, swallowing 
function, and salivary flow rates, were assessed pretreatment 
(baseline) as well as twice posttreatment. Shoulder function 
was not assessed at baseline. The first posttreatment fol-
low-up was performed around 3 months (3-month follow-up) 
after last treatment day (mean 99 days, range 55–195) includ-
ing adjuvant treatment if received. The second posttreatment 
follow-up was performed 12  months (12-month follow-up) 
after treatment start (mean 377 days, range 335–447). Last 
treatment day was chosen as the anchoring point for the first 
follow-up as RT takes time to administer and adverse effects 
accumulate over the treatment period and 3  months after 
treatment start would be 1½–2 months after completion of 
treatment for patients receiving RT. The anchoring point was 
treatment start for the second follow-up to align with survival 
and recurrence data.
2.3 | Functional outcome measures
2.3.1 | Salivary flow rate
Salivary flow rate was assessed using the drooling method7 
(see Appendix for details). Flow rates were calculated in ml/
min.
2.3.2 | Imaging based swallowing assessments
Patients were examined using fiberoptic evaluation of swal-
lowing (FEES) and video fluoroscopy (VF) on the same day. 
The same boluses were administered at both examinations: 
15  ml water (International Dysphagia Diet Standardisation 
Initiative, IDDSI, level 0), 15  ml of moderately thickened 
water (IDDSI level 3) and one bite of white bread (IDDSI 
level 7).8
VF was evaluated using DIGEST. DIGEST grades are 
based on patterns of penetration/aspiration and pharyngeal 
residue to derive an overall severity grade of dysphagia that 
aligns to CTCAE toxicity grading framework; from grade 
0 (best function), grade 1 (mild), grade 2 (moderate), grade 
3 (severe), to grade 4 (profound/life threatening dysphagia, 
worst function).9
FEES was analyzed using the Yale Pharyngeal Residue 
Severity Rating Scale (Yale) for residue at the vallecula and 
the piriform sinus,10 and was assessed after the last swallow 
of the bolus.
2.3.3 | CvB scale
As a crude guide to subjective swallowing function patients 
were asked at 3- and 12-month follow-up: “If your pre-illness 
(precancer) swallowing function was 10 out of 10. What is it 
now on a scale from 1 to 10, where 1 is the worst imagina-
ble function?”. By predefining 10 out of 10 as the pre-illness 
function, the scale only measures patients’ perceived dete-
rioration in swallowing function. The scale, named after its 
inventor (and co-author), was invented for this study, and has 
not previously been used or validated.
2.3.4 | MD Anderson Dysphagia Inventory 
(MDADI)
MDADI is a 20-question swallowing related QoL question-
naire. It can be summarized in two overall functional scores: 
one based on a single question (global score) and the other 
based on the remaining 19 questions (composite score). The 
composite score ranges from 20 to 100 with a higher score 
representing better QoL.11 A 10-point change in score is 
generally considered a clinically relevant difference.12 The 
19 questions making up the composite score can also be re-
ported in three subscales (emotional, functional and physi-
cal). As part of the Swedish translation of the MDADI four 
additional questions were added; labeled X1-X4. These were 
included in the validated Danish translation and the results 
are displayed as a subscale termed X-scale (see Appendix for 
full questions).13
2.3.5 | EORTC-C30 and EORTC-H&N35
EORTC-C30 and H&N35 comprises several scales that 
can be divided into functional, global health, and symptom 
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scales. All scales and single-item measures are normalized 
to range from 0 to 100, where a high score represents high 
QoL for the functional scales (physical, emotional, cog-
nitive, and social) and global health status. Conversely, a 
high symptom scale score indicates a high level of symp-
tomatology (low QoL). The minimal clinically important 
difference was set as 10% of the maximum instrument 
score (i.e. 10 points).14
2.3.6 | Neck Dissection Impairment Index 
(NDII)
An unvalidated Danish translation of the neck dissection im-
pairment index, version 1 was used.
NDII comprises 10 questions all of which are rated on a 
5-point Likert scale. The scores can be summarized in a total 
score ranging from 0 to 100, where a high value represents 
good function.15 An 18-point change was considered clini-
cally meaningful.16
2.3.7 | Oxford shoulder score (OSS)
Similar to the NDII patients were asked to complete the OSS 
at 3- and 12-month follow-up.
The OSS was developed to assess all types of shoulder 
conditions (apart from instability). It comprises 12 questions 
scored from 0 (poor) to 4 (best). The 12 question scores are 
added to a total score that ranges from 0 to 48, with a high 
score representing good function.17
2.4 | Statistical analysis
Statistical analyses were conducted using SPSS, version 25 
(IBM Inc). All outcomes were compared for each treatment 
group between baseline and 12-month follow-up, except for 
shoulder scores. When differences in scores were not nor-
mally distributed (DIGEST and FEES related scores: PAS 
and Yale) nonparametric signed rank test was used with the 
effect size (r) and 95% CIs. The magnitude of the effect size 
was interpreted in accordance with Cohen Benchmarks with 
r  =  0.10, small; r  =  0.30, medium; and r  =  0.50, large.18 
For outcomes where the differences were normally distrib-
uted (salivary flow rates, CvB, MDADI, EORTC-C30 and 
-H&N35 scores) comparison was made using the dependent 
t test.
Missing data in QoL questionnaires and functional swal-
lowing assessments were not statistically replaced. However, 
for OSS only, and in accordance with the developer's guide-
lines one or two missing values were replaced with an aver-
age of the remaining question scores.17
3 |  RESULTS
In the study period 110 patients met the inclusion criteria, 32 
patients undergoing TORS were included versus 13 patients 
undergoing RT. Of the remaining 65 patients 31 received RT 
in a different hospital, and 34 received RT at our hospital 
but declined to participate. Informed consent was needed for 
inclusion.
Patient characteristics are reported in Table 1. The most 
common primary tumor site was palatine tonsil (68%) fol-
lowed by base of tongue (25%) and soft palate (7%).
In the TORS group, five (16.1%) had hemorrhages re-
quiring treatment (range perioperatively—17  days), one of 
which was an arterial bleed upon extubation, an emergency 
tracheotomy was performed to regain control of the airway 
and reverted when hemostasis was achieved. Fourteen (45%) 
had midline malignancies (base of tongue or soft palate) and 
received bilateral neck dissection. Four (12.9%) were treated 
for aspiration pneumonia (range 5–12 days postoperatively). 
One patient (3.2%) was upstaged during TORS to a T4 and 
referred to adjuvant chemoradiotherapy (CRT). Four (12.9%) 
were found to have ENE on final pathology and were referred 
to adjuvant CRT. One declined and presented with N-site 
failure at 6 months at which time he received salvage CRT. 
The average length of stay after TORS was seven days (range 
4–46 days).
In the RT group, 13(100%) completed radiotherapy (66–
68 Gy), nine (69%) tolerated Cisplatin, and all 13 received 
Nimorazole. Nine (69.2%) had bilateral neck radiation, and 
three (23.1%) had selective neck dissections for suspected 
recurrence within 12-month follow-up (range 2–9 months). 
Seven (53.8%) were admitted to hospital with overnight stays 
a total of 12 times, 10 admissions were due to side-effects of 
treatment (nausea, vomiting, pain, dehydration, and reduced 
oral intake), one due to neutropenic fever and one as part of 
investigations for possible recurrence. Four (30.1%) did not 
complete the 3-month follow-up, one of whom declined fol-
low-up after completing treatment.
The mean follow-up time was 26 months (range 17–34). 
Two patients died within the follow-up period.
3.1 | Salivary flow rate
Changes in mean salivary flow rate compared to baseline 
(where a low value represents a decrease in flow rate) are 
shown in Figure 1.
When comparing baseline to 12-month follow-up, the 
TORS group had a significant increase in stimulated flow 
rate, with a mean change of 0.1 ml/min (95% CI of change 
0.0–0.2, p = 0.046). In the RT group there was a significant 
decline in both stimulated and unstimulated flow rates. With 
a mean decline of 0.38 ml/min in both flow rates, the 95% CI 
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of the change was −0.5 to −0.2 in the stimulated and −0.6 to 
−0.2 in the unstimulated flow rate with p values of >0.001 
and 0.002, respectively.
3.2 | Imaging assessed swallowing function
Comparison of baseline to 12-month follow-up scores 
showed significantly higher DIGEST scores (worse func-
tion) in both treatment groups, with the highest grade at 
any time point being 2 (moderate dysphagia). In the TORS 
group 26% of patients had increased scores at 12-month 
follow-up (r = 0.5, 95% CI 0.12–0.62, p = 0.009) in the RT 
group it was 39% (r = 0.6, 95% CI 0.09–0.74, p = 0.025). 
The change in DIGEST scores was driven mainly by an 
increase in efficiency scores. In the TORS group, the in-
crease was significant with an effect size of 0.50 (95% CI 
0.19–0.94, p = 0.007), while it was 0.50 (95% CI −0.01–
1.01, p = 0.063) in the RT group. DIGEST grades at each 
time point are shown in Figure 2A.
Four patients (9%) had DIGEST scores of 2 at 12-month 
follow-up (see Figure 2A). All four had TORS for palatine 
tonsillar malignancies, two had received adjuvant CRT.
In the FEES-related scores, there was no significant 
change in PAS when comparing baseline to 12-month fol-
low-up in either treatment group, but a significant increase 
(more retention) in Yale scores at the vallecula (r  =  0.5, 
95% CI 0.55–1.10, p > 0.001) in the TORS and in the RT 
group (r = 0.4, 95% CI 0.17–1.10, p = 0.009). The TORS 
group also showed significant increase (more retention) at 
the piriform sinus (r = 0.5, 95% CI 0.39–0.89, p > 0.001) 
with no significant change in the RT group (r = 0.3, 95% CI 
−0.06–0.73, p = 0.108). Retention scores at each time point 
are shown in Figure 2B.
3.3 | CvB scale
At baseline (pre-illness), the CvB score was pre-defined as 
10 corresponding to 100% functionality. Scores for each 
treatment group at each time point is shown in Figure 2C.
Comparing baseline to 12-month follow-up scores showed 
significant declines (worse function) in both treatment groups 
with a mean decline of 19% in the TORS group (95% CI of 
change −25.7 to −11.7, p > 0.001) and 28% in the RT group 
(95% CI of change of −39.0 to −15.6, p > 0.001).
3.4 | QoL
Subscales and composite scores, corresponding to the func-
tional outcomes (pain, swallowing function, and saliva flow 
rate) from baseline to 12-month follow-up for MDADI, 






58 (46–78) 59 (46–78) 58 (51–72)
Sex
Male 33 (75%) 22 (71%) 11 (85%)
Female 11 (15%) 9 (29%) 2 (15%)
Primary tumor location
Palatine tonsil 30 (68%) 22 (71%) 8 (62%)
Base of tongue 11 (25%) 6 (19%) 5 (38%)
Soft palate 3 (7%) 3 (10%) 0
Clinical TNM
T1 n (%) 21 (48%) 15 (48%) 6 (46%)
T2 n (%) 20 (45%) 16 (52%) 4 (31%)
T3 n (%) 1 (2%) 0 1 (8%)
T4 n (%) 2 (5%) 0 2 (15%)
N0 n (%) 16 (36%) 16 (52%) 0
N1 n (%) 27 (61%) 15 (48%) 12 (92%)
N2 n (%) 1 (2%) 0 1 (8%)
UICC8 stage, n (%)
I 41 (93%) 31 (100%) 10 (77%)
II 1 (2%) 0 1 (8%)








36 (82%) 24 (77%) 12 (92.3%)
Smoking status
Never smoker 14 (32%) 11 (35%) 3 (23%)
0–10 pack 
years
5 (11%) 3 (10%) 2 (15%)
>10 pack years 25 (57%) 17 (55%) 8 (62%)
Radiotherapy 18 (41%) 5 (16%) 13 (100%)
Chemotherapy
Cisplatin 13 (30%) 4 (13%) 9 (69%)
Carboplatin 1 (3%) 0
Nimorazol 15 (34%) 2 (7%) 13 (100%)
ASA
ASA 1 21 (48%) 13 (42%) 8 (62%)
ASA 2 18 (41%) 16 (52%) 2 (15%)






Abbreviations: ASA, American Society of Anesthesiologist Classification; 
cTNM, clinical TNM stage (UICC 7); HPV, Human Papilloma Virus; RT, 
radiotherapy; TORS, Trans Oral Robotic Surgery.
6 |   SCOTT eT al.
EORTC-C30, and EORTC H&N35 are shown in Figure 3. 
Full results are listed in Appendix.
3.5 | MDADI
When comparing baseline to 12-month follow-up scores, 
in a post-hoc analysis, we found only four question scores 
showed significant changes. In the TORS group, it was 
only two question: P7 (It takes me longer to eat because of 
my swallowing problem; mean change 0.7, 95% CI 0.07–
1.35, p  =  0.031) and the Swedish translation added item 
X4 (I have to use liquids to clear when I eat; mean change 
0.7, 95% CI 0.08–1.23, p = 0.029). In the RT group, it was: 
P4 (I feel that I am swallowing a huge amount of food, 
mean change 1.0, 95% CI −0.01–2,01, p = 0.048), P7 (see 
above, mean change 1.25, 95% CI 0.01–2.50, p = 0.040), 
X2 (the food sticks when I swallow, mean change 1.2, 95% 
CI 0.36–1.97, p = 0.023), and X3 (swallowing is difficult 
because I have a dry mouth, mean change 1.8, 95% CI 
0.94–2.73, p = 0.008).
3.6 | Shoulder function
Total scores for both questionnaires panel by treatment were 
similar and mostly unchanged (Figure 4).
4 |  DISCUSSION
QoL and functional outcomes should be a factor in 
OPSCC treatment decisions, with emphasis on individu-
alized treatment as patients will have different functional 
requirements affecting their QoL. In this descriptive, 
hypothesis-generating feasibility study we present a com-
prehensive examination of patients treated with either 
TORS or RT focused on known adverse effects and com-
plications of both modalities.
Xerostomia is a well-known adverse effect of RT and in 
a comparative study Xu et al19 reported significantly worse 
xerostomia scores for patient treated with RT (as single or 
part of multi-modality treatment) compared to surgery alone. 
For patients treated with RT, we found declined saliva flow 
rates and reported xerostomia scores at the 12-month fol-
low-up. For patients treated with TORS, we found, a slight 
but significant increase (improvement) in stimulated salivary 
flow rate and an increase in the sticky saliva subscale of the 
EORTC-H&N35 at the 12-month follow-up. Taken together, 
this may represent a change in the viscosity of the saliva due 
to a decreased clearing in the resected area but warrant fur-
ther studies.
Longitudinal data on imaging based swallowing assess-
ments after TORS is still rare. Lazarus et al20 only reported 
none to mild dysphagia (DIGEST <2) on MBS evaluations 
comparing pre- to 1-month postoperative scores, while 
Hutcheson et al21 found a prevalence of moderate to severe 
dysphagia (DIGEST ≥2) of 6.7% for patients treated with 
TORS and 15.9% for patients treated with RT when assessing 
257 patients treated for oropharyngeal cancer 3 to 6 months 
after treatment. We found, the cohort to generally have good 
swallowing function, on imaging studies, with no severe 
dysphagia within 1 year and a low prevalence of moderate 
dysphagia. However, both treatment groups showed signif-
icant worsening on imaging based swallowing assessments 
at 12-month follow-up. This is corroborated by the signif-
icant declines (worse function) in patients’ perception of 
their swallowing recovery per CvB scores in both treatment 
groups as well as image-based assessments showing a signif-
icant increase in pharyngeal retention.
F I G U R E  1  Change in mean salivary flow from follow-up to baseline. Negative values represent a mean decline in salivary flow rate (ml/min)
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F I G U R E  2  Pre- and posttreatment imaging studies results. A, Pre- and posttreatment DIGEST grade paneled by treatment. Grade 0 = no 
dysphagia, grade 1 = mild dysphagia, grade 2 = moderate dysphagia, grade 3 = severe dysphagia, and grade 4 = life threatening dysphagia. B, Pre- 
and posttreatment Yale Pharyngeal Residue Severity Score paneled by treatment. C, Pre- and posttreatment CvB score (%) paneled by treatment. 
CvB score is set at 100% at baseline at subsequent visits patients are asked to compare current function to their baseline (pre-illness) function. The 
accessory nerve was sacrificed during neck dissection of one patient (3.2%) in the TORS group, who had notably worse results compared to the rest 
of the group. RT, Radiotherapy; TORS, Trans Oral Robotic Surgery
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Currently, there is a drive to examine OPSCC treatment mo-
dalities with QoL endpoints (e.g. ORATOR,22 QoLATI23 and 
PATHOS24). The most commonly used QoL questionnaires 
including the ones used in this study (MDADI, EORTC-C30, 
and -H&N35) were developed on a patient population pre-
dominantly treated with RT or CRT. These measures may, 
therefore, not fully represent all issues relating to surgical 
resection. In all three QoL questionnaires, in this study, the 
only change for the worse, we found in the TORS group, was 
in the “sticky saliva” subscale. Furthermore, we found im-
provements in the EORTC-C30 “global QoL,” which were 
both significant and clinically important. When examining 
individual questions of MDADI, we only found a statistically 
significant difference in scores for two question (“It takes me 
longer to eat because of my swallowing problem” and “I have 
to use liquids to clear when I eat”). While this likely reflects 
good QoL after TORS, there is a possibility that more surgi-
cally oriented questionnaires might uncover other factors that 
impact QoL that are simply not detected in QoL instruments 
largely validated in non-surgically treated cohorts. In contrast 
the RT group, had significant and clinically important wors-
ening in “X-scale” of MDADI (mean difference 16.3), as well 
as before mentioned “dry mouth” and “sticky saliva” of the 
EORTC-H&N35, with clinically important but not signifi-
cant worsening in “senses problems” (mean difference 12.5).
Treatment related shoulder impairment is a potential ad-
verse effect of both surgical and RT treatment of the neck,19 
we included questionnaires to explore the scale of impair-
ment. We used the NDII and the OSS and found both ques-
tionnaires to reflect some impairment at 3-month follow-up 
in the RT group which improved at 12-month follow-up. 
The shoulder questionnaires were not part of the baseline 
F I G U R E  3  Heatmap of all subscales and composite scores that showed statistically significant or clinically meaningful changes from baseline 
to 12-month follow-up for MDADI, EORTC-C30, and EORTC H&N35. EORTC-C30, European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Core Module; EORTC-H&N35, EORTC Head & Neck Module; MDADI, MD Anderson Dysphagia Index; 
TORS, Trans Oral Robotic Surgery. X-scale based on four questions added onto the questionnaire, when it was translated into Swedish (please 
see Appendix for the questions). p values under 0.005 are marked in bold. Color codes show changes bigger than the minimal clinically important 
difference (CID, set as 10% of the maximum instrument score if not otherwise stated in methods). Grey = no clinically important change, dark 
green = improvements between 11 and 20% more than CID, orange = decline between 11 and 20% more than CMI, red = decline between 21 and 
30% more than CMI, dark red = decline between 41 and 50 more than CMI
Baseline 12 months Baseline 12 months
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
MDADI
Composite 93,3(12,8) 90,5(15,2) -2.8 0.402 90(12) 85(13.8) -5.5 0.337
Functional scales (100 = favourable)
Global QoL 68.8(23.8) 80.4(20.6) 11.6 0.004 65.4(18.9) 76.4(19.1) 9.7 0.032
Symptom scales/itesms (100 = unfavourable)
Pain 9.1(11.7) 8.9(13.8) -0.3 0.919 29.9(19.9) 11.1(14.8) -18.8 0.037
Swallowing 7.5(16.4) 8.3(18) 0.8 0.84 13.2(14) 13.4(12.5) 0.2 0.961
Dry mouth 9.7(19.6) 18.3(29.6) 8.6 0.058 11.1(21.7) 58.3(32.2) 47.2 >0.001
Sticky saliva 11.8(25.2) 26.9(33.8) 15.1 0.024 8.3(20.7) 36.1(36.1) 27.8 0.025











F I G U R E  4  Neck Dissection Impairment Index and Oxford Shoulder Score total scores. Bars, 95% confidence interval; black line, maximum 
(best) possible score; TORS, Trans Oral Robotic Surgery; RT, radiotherapy
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assessment so we cannot conclude if baseline function was 
recovered but the TORS group showed very stable, low lev-
els of impairment. The difference in impairment might be 
explained by the higher percentage of RT patients who re-
ceived bilateral neck radiation compared to TORS patients 
who underwent bilateral neck dissections, 69% versus 45%, 
respectively.
In a post hoc analysis, the five TORS patients who re-
ceived CRT within a year of treatment (four as adjuvant and 
one as salvage treatment) were found to have the worst out-
comes compared to single modality TORS and CRT with 
regards to swallowing function (imaging assessed and CvB 
score) as well as QoL scores with similar shoulder function 
results to the CRT group.
This study had several limitations which should caution 
the interpretation of the results. The small sample size, par-
ticularly in the RT group, limits power to detect significant 
changes in outcome measures. Selection bias because only 
T1-2 and N0-1 were considered for TORS. Lastly, while all 
but one eligible TORS patients were included in this study, 
patients receiving RT were less inclined to participate evident 
in the low number of patients enrolled compared to eligible 
patients in this group possibly skewing the results.
The most notable strength of this study is the comprehen-
sive examination of this OPSCC cohort, collecting multiple 
measures at set time points. These outcomes will help to in-
form a larger scale, preferably randomized study to more ac-
curately assess treatment related differences and severity in 
the adverse effects. We found several significant differences 
between baseline and 12-months follow-up scores with over-
all good functional and QoL outcomes 1 year after treatment 
for OPSCC regardless of modality.
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APPENDIX 
SALIVARY FLOW RATE -  METHODS
Salivary flow rate was assessed using the drooling method 
with 5  min of unstimulated collection time followed by 
1 min of stimulation by chewing a paraffin gum after this 
was discarded a stimulated sample was collected over a 
5-min period. Samples were collected between 12 am and 
1 pm. Prior to sampling the patient had been fasting for an 
hour.
Saliva sample size was estimated under the assumption 
that 1 milliliter (ml) of saliva weighs one gram (g).23
SWALLOWING FUNCTION - 
METHODS
VF was performed using standard fluoroscopy equipment 
with the patient sitting during the study. Visipaque and 
barium paste were used as contrast agents. Liquid boluses 
were administered on a syringe. Each bolus was analyzed 
using DIGEST and Penetration Aspiration Scale (PAS) was 
assessed throughout the recorded swallows for each bolus. 
DIGEST ranges from grade 0 (best function) to 4 (worst). 
It was developed specifically for head and neck cancer 
patients.9
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FEES was performed using a fiber-endoscope connected 
to a recording device (MediCap® USB200 or 300) record-
ing both video and audio. Only an anecdotal number of 
examinations were performed with the use of local anes-
thetic agents (Lidocaine). All liquid boluses were adminis-
tered on a syringe. Each bolus was analyzed with regards to 
the Yale Pharyngeal Residue Severity Rating Scale (Yale) 
score at the vallecula and the piriform sinus. Assessments 
were made when the patient felt they had swallowed the 
bolus regardless of how many swallows were used to get 
there. PAS was assessed throughout all attempts to swal-
low the bolus.
If a bolus could not be swallowed maximum points were 
awarded for retention/residual and PAS left as a missing 
value, in both VF and FEES.
MDADI x-scale questions.
X-scale questions (translated into English from Danish):
X1: It hurts when I eat/drink/swallow.
X2: The food sticks when I swallow.
X3: Swallowing is difficult because I have a dry mouth.
X4: I must use liquids to clear when I eat.
FIGURE A1. Baseline and 12-month follow-up results 
for MDADI, EORTC-C30, and -H&N35 for each treatment 
group. EORTC-C30, European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire Core 
Module; EORTC-H&N35, EORTC Head & Neck Module; 
MDADI, MD Anderson Dysphagia Index; TORS, Trans Oral 
Robotic Surgery. X-scale based on four questions added onto 
the questionnaire, when it was translated into Swedish (please 
see below for the questions). p values under 0.005 are marked in 
bold. Color codes show changes bigger than the minimal clin-
ically important difference (CID, set as 10% of the maximum 
instrument score if not otherwise stated in methods). Grey = no 
clinically important change, dark green  =  improvements be-
tween 11% and 20% more than CID, orange = decline between 
11 and 20% more than CMI, red = decline between 21% and 
30% more than CMI, dark red = decline between 41 and 50 
more than CMI
FIGURE A2. Longitudinal MDADI results at all three 
timepoints paneled by treatment
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TORS Radiotherapy
Time Point Paired Differences Time Point Paired Differences
Baseline 12 months Baseline 12 months
Mean (SD) Mean (SD)
Mean 
change 95% CI p Mean (SD) Mean (SD)
Mean 
change 95% CI p
Composite 93,3(12,8) 90,5(15,2) –2.8 (–9.4;3.9) 0.402 90(12) 85(13.8) –5.5 (–17.6;6.6) 0.337
Composite incl. X 
scale 92(13,8) 88,6(16) –3.4 (–10.3;3.6) 0.333 87.6(11.6) 79.7(15) –8.2 (–20.2;3.8) 0.161
Added scale (X 
scale) 87,9(17,8) 82,7(20,3) –5.1 (–13.6;3.4) 0.226 80.4(17) 63.8(21.4) –16.3 (–31.5;–1.0) 0.038
Emotional 93,3(13,5) 91,3(15,6) –2.0 (–9;5.1) 0.569 91.5(12.2) 87.5(13.7) –3.6 (–15.9;8.7) 0.531




Physical 91,7(14,5) 87,2(17,1) –4.5 (–12.2;3.2) 0.24 86(16.8) 77.7(16.9) –9.4 (–24.2;5.4) 0.191
Functional scales (100 = favourable)
Global QoL 68.8(23.8) 80.4(20.6) 11.6 (3.9;19.2) 0.004 66.7(19.1) 76.4(19.1) 9.7 (1;18.4) 0.032
Physical 88.6(20.8) 91.8(15.2) 3.2 (–2.6;9) 0.266 86.1(19) 91.1(13.4) 5.0 (–6.3;16.3) 0.351
Role 90.3(16.5) 93(15.4) 2.7 (–2.3;7.7) 0.282 81.9(26.1) 88.9(20.5) 6.9 (–6.9;20.8) 0.295
Emotional 71(22.8) 88.7(18.3) 17.7 (10.4;25.1) >0.001 75.7(19) 90.3(12.7) 14.6 (4.5;24.7) 0.009
Cognitive 83.3(19.7) 89.2(18.5) 5.9 (–0.3;12.1) 0.062 86.1(17.2) 80.6(15.6) –5.6 (–17.8;6.7) 0.339
Social 91.9(17.1) 95.2(15) 3.2 (–2.3;8.8) 0.246 88.9(17.9) 84.7(16.6) –4.2 (–17;8.7) 0.491
Symptom scales/itesms (100 = unfavourable)
Fatigue 20.8(19) 14(17.2) –6.8 (–13.5;–0.1) 0.047 33.3(23.2) 24.1(18.9) –9.3 (–21.6;3.1) 0.127
Nausea/vomitting 1.6(6.6) 0.5(3) –1.1 (–3.8;1.6) 0.423 0(0) 0(0) N/A N/A N/A
Pain 11.8(21.6) 9.1(16.6) –2.7 (–9.8;4.4) 0.444 23.6(18.1) 15.3(21.9) –8.3 (–22.3;5.6) 0.214
Dyspnoea 14(20.7) 7.5(16.6) –6.5 (–14.5;1.5) 0.11 8.3(15.1) 2.8(9.6) –5.6 (–17.8;6.7) 0.339
Insomnia 24.7(28.5) 12.9(23.8) –11.8 (–23.9;0.2) 0.054 25(28.9) 30.6(30) 5.6 (–14.3;25.4) 0.551
Appetite loss 11.8(16.2) 4.3(11.4) –7.5 (–14.4;–0.7) 0.032 13.9(22.3) 11.1(16.4) –2.8 (–16.9;11.4) 0.674
Constipation 7.5(18.7) 2.2(12) –5.4 (–10.9;0.2) 0.057 2.8(9.6) 0(0) –2.8 (–8.9;3.3) 0.339






Financial difficulties 3.2(13.2) 4.3(18.7) 1.1 (–5.6;7.8) 0.745 5.6(13) 13.9(26.4) 8.3 (–7.6;24.3) 0.275
Symptom scales/itesms (100 = unfavourable)
Pain 9.1(11.7) 8.9(13.8) –0.3 (–5.6;5.1) 0.919 29.9(19.9) 11.1(14.8) –18.8 (–36.1;–1.4) 0.037
Swallowing 7.5(16.4) 8.3(18) 0.8 (–7.3;8.9) 0.84 13.2(14) 13.4(12.5) 0.2 (–9.9;10.3) 0.961
Senses problems 8.6(14.2) 7(15.4) –1.6 (–9.1;5.9) 0.662 9.7(20.7) 22.2(31.2) 12.5 (–7.2;32.2) 0.191
Speech problems 7.2(10.2) 5(9.4) –2.2 (–5.7;1.4) 0.226 6.1(7.6) 8.1(11.2) 2.0 (–3.6;7.6) 0.441
Trouble w. social 
eating 5.1(11.7) 5.6(15.1) 0.5 (–6.5;7.6) 0.877 6.8(11.1) 9.8(12.8) 3.0 (–7.4;13.4) 0.531
Trouble w. social 







Less sexuality 26.4(37.4) 20.7(32.9) –6.0 (–21.5;9.6) 0.439 16.7(23.6) 23.3(27.4) 6.7 (–8.4;21.7) 0.343
Teeth 11.8(28) 15.1(27) 3.2 (–9.1;15.6) 0.598 22.2(35.8) 16.7(33.3) –5.6 (–20.8;9.6) 0.438
Opening mouth 0(0) 7.5(20.6) 7.5 (0;15.1) 0.050 5.6(13) 11.1(21.7) 5.6 (–9.6;20.8) 0.438
Dry mouth 9.7(19.6) 18.3(29.6) 8.6 (–0.3;17.5) 0.058 11.1(21.7) 58.3(32.2) 47.2 (30.4;64) >0.001
Sticky saliva 11.8(25.2) 26.9(33.8) 15.1 (2.1;28) 0.024 8.3(20.7) 36.1(36.1) 27.8 (4.2;51.4) 0.025
Coughing 20.4(18.6) 17.2(24.1) –3.2 (–13.9;7.4) 0.540 22.2(21.7) 16.7(17.4) –5.6 (–23.2;12.1) 0.504
Felt ill 11.8(18.4) 8.6(21) –3.2 (–11.8;5.3) 0.448 8.3(20.7) 5.6(13) –2.8 (–19.6;14) 0.723
Pain killers 14(16.7) 8.6(14.8) –5.4 (–12.5;1.8) 0.134 21.2(22.5) 12.1(16.8) –9.1 (–26.7;8.5) 0.277
Nutritional 
supplements 6.5(13.4) 6.5(13.4) 0.0 (–7.1;7.1) 1.000 0(0) 6.1(13.5) 6.1 (–3;15.1) 0.167
Feeding tube 0(0) 0(0) N/A N/A N/A 0(0) 0(0) N/A N/A N/A
Weight loss 1.1(6) 3.2(10) 2.2 (–2.2;6.5) 0.325 3(10.1) 0(0) –3.0 (–9.8;3.7) 0.341
Weight gain 4.3(11.4) 7.5(14.2) 3.2 (–2.6;9.0) 0.264 12.1(16.8) 9.1(15.6) –3.0 (–18.7;12.7) 0.676
Completed, n 31 31 13 12
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